These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 22366593)
21. Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma. Rauh-Hain JA; Growdon WB; Schorge JO; Goodman AK; Boruta DM; McCann C; Horowitz NS; del Carmen MG Gynecol Oncol; 2010 Nov; 119(2):299-304. PubMed ID: 20691465 [TBL] [Abstract][Full Text] [Related]
22. Prognostic implication of endometriosis in clear cell carcinoma of the ovary. Orezzoli JP; Russell AH; Oliva E; Del Carmen MG; Eichhorn J; Fuller AF Gynecol Oncol; 2008 Sep; 110(3):336-44. PubMed ID: 18639330 [TBL] [Abstract][Full Text] [Related]
23. [Prognostic analysis of 88 patients with ovarian clear cell carcinoma]. Ma SK; Zhang HT; Wu LY; Liu LY Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):784-8. PubMed ID: 18396695 [TBL] [Abstract][Full Text] [Related]
24. [Prognostic value of serum CA(125) level change during chemotherapy post-surgery in patients with advanced epithelial ovarian carcinoma]. Lan CY; Huang H; Liu JH Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):732-6. PubMed ID: 19087537 [TBL] [Abstract][Full Text] [Related]
25. [Clinical characteristics and multivariate analysis of prognostic factors in recurrent laryngeal carcinoma]. Chen YF; Chen FJ; Yang AK; Zeng ZY; Song M; Li QL Ai Zheng; 2004 May; 23(5):584-8. PubMed ID: 15142460 [TBL] [Abstract][Full Text] [Related]
26. Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation. Hoskins PJ; Le N; Gilks B; Tinker A; Santos J; Wong F; Swenerton KD J Clin Oncol; 2012 May; 30(14):1656-62. PubMed ID: 22493415 [TBL] [Abstract][Full Text] [Related]
27. Patterns of Care, Predictors, and Outcomes of Adjuvant Therapy for Early- and Advanced-Stage Uterine Clear Cell Carcinoma: A Population-Based Analysis. Gockley AA; Rauh-Hain JA; Anders AM; Meyer LA; Clemmer J; Lu KH; Clark RM; Schorge JO; del Carmen MG Int J Gynecol Cancer; 2016 May; 26(4):697-704. PubMed ID: 26825834 [TBL] [Abstract][Full Text] [Related]
30. [Multidisciplinary treatment of recurrent epithelial ovarian carcinoma and prognostic analysis]. Huang X; Cai SM; Tang J; Li ZT; Zang RY Zhonghua Fu Chan Ke Za Zhi; 2004 Sep; 39(9):602-5. PubMed ID: 15498187 [TBL] [Abstract][Full Text] [Related]
31. [Treatment and prognostic factors for stage IV epithelial ovarian cancer]. Wu M; Shen K; Lang J Zhonghua Fu Chan Ke Za Zhi; 2000 Apr; 35(4):200-3. PubMed ID: 11776158 [TBL] [Abstract][Full Text] [Related]
32. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584 [TBL] [Abstract][Full Text] [Related]
33. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC; Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296 [TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Le T; Alshaikh G; Hopkins L; Faught W; Fung MF Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146 [TBL] [Abstract][Full Text] [Related]
35. The role of optimal debulking in advanced stage serous carcinoma of the uterus. Moller KA; Gehrig PA; Van Le L; Secord AA; Schorge J Gynecol Oncol; 2004 Jul; 94(1):170-4. PubMed ID: 15262137 [TBL] [Abstract][Full Text] [Related]
36. Cytoreductive surgery for stage IV epithelial ovarian cancer. Zang RY; Zhang ZY; Cai SM; Li ZT; Chen J; Tang MQ; Liu Q J Exp Clin Cancer Res; 1999 Dec; 18(4):449-54. PubMed ID: 10746968 [TBL] [Abstract][Full Text] [Related]
37. [Factors affecting disease recurrence and the role of secondary therapies in the management for patients with recurrent ovarian carcinoma]. Zang R; Zhang Z; Cai S Zhonghua Fu Chan Ke Za Zhi; 2002 Sep; 37(9):546-9. PubMed ID: 12411017 [TBL] [Abstract][Full Text] [Related]
38. Ovarian clear cell carcinoma, outcomes by stage: the MSK experience. Shu CA; Zhou Q; Jotwani AR; Iasonos A; Leitao MM; Konner JA; Aghajanian CA Gynecol Oncol; 2015 Nov; 139(2):236-41. PubMed ID: 26404183 [TBL] [Abstract][Full Text] [Related]
39. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging? Dizon DS; Restivo A; Lomme M; Charbonneau N; Brard L; Hughes T; Weitzen S; Legare R; Granai CO; Disilvestro P Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226 [TBL] [Abstract][Full Text] [Related]
40. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Sugiyama T; Kamura T; Kigawa J; Terakawa N; Kikuchi Y; Kita T; Suzuki M; Sato I; Taguchi K Cancer; 2000 Jun; 88(11):2584-9. PubMed ID: 10861437 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]